Artiva Biotherapeutics, Inc.
$7.26
+2.6%Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -2.1).
Valuation inputs: P/E -2.1, earnings yield N/A, momentum +2.6%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -76.3%, ROIC -74.9%).
Profitability stack: net margin 0.0%, ROE -76.3%, ROIC -74.9%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +16.0%, momentum +2.6%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Artiva Biotherapeutics, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Artiva Biotherapeutics, Inc. Fair Value Envelope
Artiva Biotherapeutics, Inc. Profit Bridge
Profitability Analysis
Artiva Biotherapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Artiva Biotherapeutics, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Artiva Biotherapeutics, Inc. Street Expectations Map
Wall Street analysts project that ARTV stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 37.50, with estimates ranging from a low of 35.00 to a high of 40.00.
The consensus 1-year price target stands at 37.50, with estimates ranging from a low of 35.00 to a high of 40.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
High analyst agreement. Narrow target range indicates strong consensus on valuation, suggesting clear investment thesis and predictable outlook.
Analyst Conviction
Strong buy conviction: High upside with tight consensus suggests compelling investment opportunity backed by analyst confidence.
Market Sentiment Insight
Rare opportunity: Exceptional upside potential with strong analyst consensus creates a compelling setup. The combination of significant price target premium and tight agreement suggests high-conviction undervaluation that may attract institutional capital.
Artiva Biotherapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $87.65M and sold $732K worth of ARTV shares, resulting in $86.92M of net buying activity.
3 Months
7.6M
87.50M
53.0K
477.77K
+87.0M
+$87.02M
3-6 Months
0
0.00
3.2K
19.12K
-19K
-$19K
6-9 Months
0
0.00
31.9K
174.52K
-175K
-$175K
9-12 Months
96.3K
154.96K
21.9K
60.25K
+95K
+$95K
Top Buyers
Ra Capital Management, L.P.
Director, 10 Percent Owner:
$75.02M
Gc Corp.
10 Percent Owner
$12.50M
Daniels Brian
Director
$22K
Moore Alison
Director
$22K
Baker Daniel G.
Director
$22K
Top Sellers
Aslan Fred
Director, Officer: Chief Executive Officer
$450K
Bush Jennifer
Officer: Coo, Clo, Compliance Officer
$97K
Horan Christopher
Officer: Chief Tech Operations Officer
$73K
Banerjee Subhashis
Officer: Chief Medical Officer
$63K
Raymon Heather
Officer: Svp, Research And Development
$32K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $86.92M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Recent Trend (3 Months)
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
Insider Participation
5 insider buyers and 5 sellers. Equal participation suggests mixed or neutral insider views.
Insider Activity Insight
Strong confluence of bullish signals: High buy/sell ratio, multiple insiders participating, and recent buying momentum all point to significant insider confidence. This level of coordinated buying often precedes positive developments.
No Dividend Yield Data
ARTV has not reported any dividend yield values in the available annual periods.
artv Dividend History
Learning Layer
Related Guides
Build conviction on ARTV by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.